Quantib, a medical technology company based out of Rotterdam, the Netherlands, has received FDA clearance for its Quantib Neurodegenerative (ND) solution.
Quantib ND uses machine learning for the automated measurement of brain atrophy and detection of white matter hyperintensities in MRI scans of the brain. Users send a scan to the workstation and pre-processing begins automatically.
In addition, Quantib ND can be used to track changes to the brain over time. The solution also offers detailed reports, which can be downloaded or uploaded to a facility’s PACS.
“This is an important achievement,” Arthur Post Uiterweer, CEO of Quantib, said in a prepared statement. “We are very proud to offer physicians an extensive software package for quantitative measurements of neurological changes that can be related to dementia and MS.”